Peer review reports
From: A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Original Submission |
29 Apr 2015 |
Submitted |
Original manuscript
|
|
Author responded |
Author comments
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
|
Author responded |
Author comments
|
|
Reviewed |
Reviewer Report
|
|
Reviewed |
Reviewer Report
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
|
Author responded |
Author comments
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
|
Author responded |
Author comments
|
Resubmission - Version 5 |
|
Submitted |
Manuscript version 5
|
|
Author responded |
Author comments
|
Resubmission - Version 6 |
|
Submitted |
Manuscript version 6
|
|
Author responded |
Author comments
|
Resubmission - Version 7 |
|
Submitted |
Manuscript version 7
|
|
Author responded |
Author comments
|
Resubmission - Version 8 |
|
Submitted |
Manuscript version 8
|
Publishing |
20 Jul 2016 |
Editorially accepted |
|
2 Aug 2016 |
Article published |
10.1186/s12894-016-0163-5
|
Learn about peer review